Retinal vasculitis

disease

On this page

Summary

Retinal vasculitis (MONDO:0006950) is a disease and 9 clinical trials. Top therapeutic interventions include corticotropin and cyclosporine. A subtype of retinal vascular disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	retinal vasculitis
Mondo ID	MONDO:0006950
EFO	EFO:1001156
MeSH	D031300
DOID	DOID:11563
ICD-10-CM	H35.06
ICD-11	1863208483
SNOMED CT	77628002
UMLS	C0152026
MedGen	57503
GARD	0024505
MedDRA	10038905
Is cancer (heuristic)	no

Also known as: retinal vasculitis

Disease family

This is a subtype of retinal vascular disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal vascular disorder › retinal vasculitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cyclosporine	Phase 3 (in late-stage trials)
INTERFERON ALFA-2A	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE4	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03066869	PHASE4	UNKNOWN	Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
NCT06613919	PHASE4	COMPLETED	Six-months Versus Nine-months ATT for Ocular TB
NCT00167583	PHASE3	COMPLETED	Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet’s Disease (INCYTOB)
NCT00050492	Not specified	COMPLETED	Biological Markers in Retinal Vasculitis
NCT01998464	Not specified	COMPLETED	Optical Coherence Tomography (OCT) in Retinal Vasculitis
NCT03264391	Not specified	COMPLETED	Evaluation of Macular Vascular Changes in Behcet’s Disease Using Optical Coherence Tomography Angiography
NCT06343961	Not specified	UNKNOWN	Intraoperative Application of Fluorescein Sodium Angiography in Vascular Retinopathy
NCT06769412	Not specified	COMPLETED	A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
NCT07105228	Not specified	COMPLETED	Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CORTICOTROPIN	4	1
CYCLOSPORINE	4	1

Drugs: Corticotropin, Cyclosporine